CHINA BRIEF 1:
Chinese Biopharmaceutical Industrial Policy--Current Development Conditions, Problems and Countermeasures in China's Biological Products Industry
Dr. WANG Changlin, Chinese Academy of Macroeconomic Research, National Development and Reform Commission
Rm 711, Building B, Guohong Mansion, No. 11 Muxidibeili Jia, Xicheng District,
Beijing, P.R. China 100038

CHINA BRIEF 2:
Distribution and Legal Strategies for Doing Business in China
Stephen DeCelle, President
350B Christopher Ave.
Gaithersburg, MD 20879 USA
Tel: +1.240.632.1188
www.3dbglobal.com

CHINA BRIEF 3:
Current Conditions & Predictions for China's Biopharmaceutical Industry Li Baoqiu
Shandong University
Jinan Association of Biological Products
School of Public Health, Shandong University
44 Wenhuaxi Road, Jinan, Shandong, P.R. China 250012

CHINA BRIEF 4:
Growth Process at Shanghai Genomics (RuiXing Gene Co): A Case Study
Huang Yi
Investment Management Department,
Shanghai Venture Capital Corporation
Floor 2, 1634 Huai Hai Rd (M), Shanghai, P.R. China 200031

CHINA BRIEF 5:
BIOGENERICS AND INTELLECTUAL PROPERTY PROTECTON IN CHINA
Eliza Yibing Zhou, Project Director, BioPlan Associates, Inc.
15200 Shady Grove Road, Suite 202 Rockville, MD 20850
301-921-9074 yb_zhou@bioplanassociates.com www.bioplanassociates.com

CHINA BRIEF 6:
Biopharmaceutical CMOs In China
Eliza Yibing Zhou, Project Director, BioPlan Associates, Inc.
15200 Shady Grove Road, Suite 202 Rockville, MD 20850
301-921-9074 yb_zhou@bioplanassociates.com www.bioplanassociates.com

CHINA BRIEF 7:
Prediction Analysis of the Technological Development Trend for the Biopharmaceutical Industry in China
Yi Hui and Chen Demian
Investment Research Institute Shanghai Tongji University
1239 Siping Road Shanghai, P.R. China (200092)
Tel:0086-21-65981143